Lester Murray Antman dba SimplyRich Has $6.38 Million Stock Position in Novo Nordisk A/S $NVO

Key Points

• Lester Murray Antman, operating as SimplyRich, increased its stock position in Novo Nordisk A/S by 6.7% to a total of $6.38 million, making it the firm's 10th largest investment.
• Novo Nordisk A/S reported a quarterly earnings per share of $0.97, exceeding analyst estimates by $0.04, with a net margin of 35.60% and a return on equity of 78.64%.
• Following recent trading, Novo Nordisk A/S saw its shares decrease by 3% to $56.95, with a current market capitalization of $254.27 billion.

Lester Murray Antman dba SimplyRich boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 6.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,403 shares of the company's stock after buying an additional 5,797 shares during the quarter. Novo Nordisk A/S makes up 1.8% of Lester Murray Antman dba SimplyRich's portfolio, making the stock its 10th largest position. Lester Murray Antman dba SimplyRich's holdings in Novo Nordisk A/S were worth $6,377,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Kingstone Capital Partners Texas LLC lifted its holdings in Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock valued at $690,560,000 after buying an additional 10,001,898 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $370,272,000. Amundi lifted its position in shares of Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company's stock worth $331,576,000 after purchasing an additional 1,627,051 shares during the period. Acadian Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock worth $72,523,000 after purchasing an additional 1,038,137 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Novo Nordisk A/S by 118.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,594,544 shares of the company's stock worth $110,725,000 after purchasing an additional 864,579 shares during the period. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 3.0%

NYSE NVO opened at $56.95 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $254.27 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 2.65 and a beta of 0.68. The company has a 50 day moving average price of $55.44 and a 200 day moving average price of $63.22. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $120.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is presently 22.53%.

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. Hsbc Global Res raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Novo Nordisk A/S in a research report on Saturday, September 27th. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a research report on Tuesday, September 16th. UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Finally, Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $77.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.